Compare Revvity Inc (RVTY) vs Trip.com Group Ltd (TCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Trip.com Group Ltd — how do they compare? Revvity Inc trades at $117.23 (market cap $12.91B), while Trip.com Group Ltd trades at $45.52 (market cap $29.10B). The key difference: Trip.com Group Ltd is far larger — about 2.3× Revvity Inc's market cap, and Trip.com Group Ltd pays the higher dividend (0.42%). Which is the better fit depends on your goals.
| RVTY | TCOM | |
|---|---|---|
Market Cap | $12.91B | $29.10B |
Sector | Technology | Consumer Cyclical |
52-Week High | $117.75 | $78.96 |
52-Week Low | $82.26 | $39.84 |
Enterprise Value | $15.23B | $21.75B |
Dividend Yield | 0.24% | 0.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $116.10, up 0.07% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.41, surpassing the $1.21 estimate, and raised its full-year outlook due to robust diagnostics demand. Revenue remains steady around $2.9 billion, with a net income margin of 8.16%. Analyst consensus is a Buy with a $120.50 price target, and recent news highlights product launches like the SuperFlex prenatal system and high-throughput TB testing platform.
The outlook for RVTY is positive, supported by earnings momentum and strategic innovations, but investors face risks from high valuation multiples and competitive pressures in the healthcare sector. The stock's proximity to its consensus target suggests limited near-term upside, requiring careful monitoring of execution against raised guidance.
Trip.com (TCOM) trades at $45.62, down 3.19% amid bearish technical signals despite strong fundamentals. The company reported robust 2025 results with $62.41B revenue and 53.34% net margin, though recent quarters show mixed earnings performance. Regulatory headwinds persist with a $770M antitrust penalty from China's market regulator in July 2026, while analyst consensus remains bullish with a $59.29 price target.
The stock faces near-term pressure from regulatory scrutiny and technical weakness, but attractive valuations (P/E 6.89) and dominant market position offer long-term upside if execution improves. Key risks include China's regulatory environment and competitive pressures, while institutional ownership shifts indicate cautious sentiment despite Wall Street's buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →
